Huntington’s disease is a progressive neurological condition that gradually damages brain cells, affecting movement, thinking, and mood. While there is no cure at present, a range of treatments can help manage symptoms and maintain quality of life, and researchers are testing promising new therapies that may one day slow or halt the disease’s progression.

Understanding treatment options for Huntington’s disease

When someone receives a diagnosis of Huntington’s disease, the first question that often arises is about treatment possibilities. The primary goal of treatment is not to cure the disease—because that option doesn’t exist yet—but rather to control symptoms, slow the decline in function, and help people maintain independence and comfort for as long as possible.^[1] Each person experiences Huntington’s disease differently, so treatment plans need to be tailored to the individual’s specific symptoms, the stage of their disease, and their personal circumstances.^[5]

Treatment approaches fall into two broad categories: standard therapies that have been approved by medical regulatory bodies and are used in everyday clinical practice, and experimental treatments currently being tested in clinical trials. Standard treatments focus on managing the physical movements, emotional changes, and cognitive difficulties that arise as the disease progresses.^[9] Meanwhile, researchers around the world are working on innovative therapies that target the underlying genetic cause of Huntington’s disease, offering hope that future treatments might actually change the course of the disease rather than just addressing symptoms.^[8]

It’s important to understand that treatment decisions depend on multiple factors, including which symptoms are most troublesome, how advanced the disease is, and what other health conditions a person might have. A team of healthcare professionals—including neurologists, psychiatrists, physiotherapists, occupational therapists, speech therapists, and social workers—typically works together to create a comprehensive care plan.^[5] This team approach recognizes that Huntington’s disease affects the whole person, not just one aspect of their health.

Standard treatment approaches for symptom management

The backbone of current Huntington’s disease treatment involves medications and therapies designed to ease specific symptoms. One of the most visible symptoms is chorea, the involuntary jerking or twisting movements that can affect the hands, face, arms, legs, and torso.^[1] These uncontrolled movements can make everyday activities like eating, speaking, and walking more difficult and can increase the risk of falls and injuries.

For chorea, doctors may prescribe a medication called tetrabenazine, which works by depleting dopamine in the brain. Dopamine is a chemical messenger involved in controlling movement, and reducing its levels can help calm the involuntary movements.^[11] Tetrabenazine is one of the more effective medications available for reducing chorea, though it does carry potential side effects. These can include drowsiness, depression, anxiety, and restlessness, so doctors must carefully monitor patients and adjust doses as needed.^[11] Some patients may not develop chorea at all; instead, they become rigid and move very little, a condition called akinesia. Others experience unusual fixed postures known as dystonia.^[1]

Newer neuroleptic medications, also called antipsychotic drugs, represent another option for managing movement problems and behavioral symptoms. Medications such as olanzapine and aripiprazole can help with chorea and also address psychiatric symptoms like agitation, irritability, and psychosis.^[11] These newer agents often have a more favorable side effect profile compared to older neuroleptic drugs, making them easier for patients to tolerate over the long term.

Beyond movement symptoms, many people with Huntington’s disease experience significant emotional and psychiatric challenges. Depression, anxiety, mood swings, and irritability are common, and these symptoms can appear even before the physical signs of disease become obvious.^[1] Antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed to help stabilize mood and reduce anxiety. Talking therapies, including cognitive behavioral therapy (CBT), can also be valuable in helping patients and their families cope with the emotional burden of the disease.^[5]

Physical rehabilitation plays a vital role in maintaining function and independence. Physiotherapy helps patients maintain muscle strength, flexibility, and balance, which can delay the worsening of movement problems and reduce the risk of falls.^[18] Exercises prescribed by a physical therapist may need to be adapted as the disease progresses, and in advanced stages, patients may require mobility aids such as walkers or wheelchairs for safety.^[18]

Occupational therapy focuses on helping people continue to perform daily activities like dressing, bathing, cooking, and managing household tasks. Therapists can recommend adaptive devices—such as utensils with larger handles, plates with raised edges, or special tools for opening containers—that make these activities easier.^[18] Modifying the home environment by removing tripping hazards, installing grab bars, and ensuring good lighting can also enhance safety and independence.^[18]

Speech and language therapy addresses problems with communication and swallowing. As Huntington’s disease affects the muscles involved in speaking and swallowing, many patients develop slurred speech and difficulty eating, which can lead to weight loss, choking, and chest infections.^[1] Speech therapists work with patients to improve clarity of speech, recommend communication aids when necessary, and teach safe swallowing techniques to reduce the risk of aspiration.^[5]

Nutritional support is another critical component of care. People with Huntington’s disease often lose weight despite eating normally, possibly due to the energy burned by constant involuntary movements and changes in metabolism.^[16] Dietitians can help develop meal plans that provide adequate calories and nutrients, and in some cases, patients may need thickened liquids or pureed foods to make swallowing safer. In advanced stages, some individuals may choose to have a feeding tube placed to ensure proper nutrition.^[16]

The duration of treatment varies because Huntington’s disease is a lifelong condition. Most people live for many years after symptoms begin—typically 15 to 20 years from diagnosis—so treatment continues throughout this period, with regular adjustments as symptoms change.^[18] The focus of care shifts from maintaining independence in the early stages to providing comfort and support in the later stages.

Promising therapies in clinical trials

While standard treatments can make life more comfortable, they don’t address the root cause of Huntington’s disease: a mutation in the HTT gene that produces an abnormal, toxic version of the huntingtin protein. This toxic protein accumulates in brain cells, particularly in regions like the striatum, and causes them to malfunction and die.^[6] Researchers have long sought ways to reduce levels of this harmful protein or prevent it from damaging neurons.

One of the most exciting recent developments is a gene therapy called AMT-130. This experimental treatment represents a fundamentally new approach to Huntington’s disease. Instead of just managing symptoms, AMT-130 aims to slow or stop the disease’s progression by reducing production of the toxic huntingtin protein.^[8]

AMT-130 works by using a modified, harmless virus as a delivery vehicle—essentially a microscopic postman—to carry new genetic instructions into brain cells. During a lengthy neurosurgical procedure lasting 12 to 18 hours, doctors use real-time MRI scanning to guide a thin tube called a microcatheter deep into specific brain regions, particularly the caudate nucleus and putamen in the striatum.^[8] The virus carrying the therapeutic DNA is then infused into these areas. Once inside the neurons, this new genetic material becomes active and turns the brain cells into factories that produce a therapy to silence the instructions for making the toxic huntingtin protein.^[8]

The initial results from clinical trials of AMT-130 have been described as “spectacular” by researchers. In a small trial involving 29 participants, those who received the higher dose of the treatment showed a 75 percent slowing of disease progression compared to what would normally be expected.^[8] This means that the decline typically seen over one year would instead take four years after treatment, potentially giving patients decades of good quality life.^[8] Some patients in the trial who were expected to need wheelchairs remained walking, and one person who had been medically retired was able to return to work.^[8]

These results come from what is known as a Phase II/III clinical trial. In drug development, Phase I trials test whether a treatment is safe in a small number of people. Phase II trials examine whether the treatment actually works and continues to be safe in a larger group. Phase III trials compare the new treatment to existing standard treatments or placebo in an even larger population to confirm effectiveness and monitor side effects.^[10] The AMT-130 trial enrolled patients in multiple locations, including sites in the United States. At the University of Alabama at Birmingham, seven of the 17 patients who received the high dose were treated.^[10]

One of the major advantages of AMT-130 is that it’s designed to be a one-time treatment. Unlike pills that must be taken daily, this gene therapy is intended to provide lasting benefits from a single dose, though the procedure itself is invasive and requires major brain surgery.^[10] Importantly, AMT-130 doesn’t permanently alter a person’s DNA; instead, it works by targeting the messenger RNA that carries instructions from DNA to make the huntingtin protein. This approach is considered safer than directly editing genes.^[10]

Other experimental approaches have also been explored in recent years. Some research has investigated using creatine, a substance that helps supply energy to cells, but large trials showed it was safe and might support muscle strength without slowing disease progression.^[11] Similarly, studies of antioxidants like CoQ10, vitamin E, and a related compound called idebenone have not demonstrated clear benefits in Huntington’s disease patients.^[11]

There has been interest in whether fish oil supplements containing omega-3 fatty acids (EPA and DHA) might help protect brain cells, as these substances have anti-inflammatory properties. However, clinical trials have not shown convincing benefits, and very high doses can carry risks such as increased bleeding or heart rhythm disturbances.^[11] Other substances tested, including cannabinoids and high doses of caffeine, have not proven beneficial, and some research suggests that high caffeine intake might even be linked to earlier symptom onset.^[11]

The mechanism of action for many experimental therapies focuses on addressing three key problems in Huntington’s disease: inflammation in the brain, oxidative stress (damage from unstable molecules called free radicals), and mitochondrial dysfunction (problems with how cells produce energy).^[11] Researchers believe that targeting these processes might help protect neurons from the toxic effects of the abnormal huntingtin protein.

Clinical trials for Huntington’s disease are conducted in various locations around the world, including the United States, Europe, and other regions. Eligibility for trials typically depends on factors such as the stage of disease, genetic confirmation of the HTT mutation, age, and overall health status. People interested in participating in clinical trials can search for opportunities through resources like HD Trialfinder, a service provided by advocacy organizations, or by discussing options with their neurologist.^[3]

It’s worth noting that some trials recruit people who have the genetic mutation but haven’t yet developed symptoms. The thinking is that starting treatment before brain damage becomes extensive might offer the best chance of preventing or delaying the onset of Huntington’s disease.^[8] This possibility is particularly significant given that symptoms typically appear in a person’s 30s or 40s, during their prime working years and at a time when they may have young families to care for.

Most common treatment methods

• Medications for movement symptoms
  • Tetrabenazine to reduce involuntary movements (chorea) by depleting dopamine in the brain
  • Newer neuroleptic medications like olanzapine and aripiprazole to manage chorea and behavioral symptoms
  • These medications require careful monitoring due to potential side effects including depression and drowsiness
• Psychiatric and behavioral treatments
  • Antidepressants, particularly SSRIs, to treat depression, anxiety, and mood swings
  • Cognitive behavioral therapy (CBT) and other talking therapies to help patients cope with emotional challenges
  • Medications to address irritability, aggression, and psychotic symptoms
• Rehabilitation therapies
  • Physiotherapy to maintain strength, balance, and flexibility and reduce fall risk
  • Occupational therapy to help with daily activities and recommend adaptive devices
  • Speech and language therapy to address communication difficulties and swallowing problems
• Nutritional support
  • Dietary counseling to ensure adequate calorie and nutrient intake
  • Modified food textures and thickened liquids for safer swallowing
  • Feeding tube placement in advanced stages when swallowing becomes too dangerous
• Gene therapy (experimental)
  • AMT-130 delivered via neurosurgery to reduce production of toxic huntingtin protein
  • Currently in Phase II/III clinical trials with promising early results showing 75% slowing of disease progression
  • Designed as a one-time treatment that may provide lasting benefits